Specialty Pharmacy

Tumors containing JAK1 and JAK2 mutations effect response to immunotherapy in patients with melanoma and colon cancer.

Application filed for ceritinib (Zykadia) as a first-line treatment for patients with metastatic non-small cell lung cancer.

Top news of the day from across the health care landscape.

The second of a 2-part interview with National Association of Specialty Pharmacy President Rebecca Shanahan on the hottest issues in specialty pharmacy.

Physical activity drops during and after cancer treatment.

Potential drug may have a protective role in chronic obstructive pulmonary disease.

Anxiety and depression linked to longer time living with HIV.

Habits such as alcohol use, along with consumption of red meat and processed meat found to influence the risk of cancer.

Extensive psoriasis lesions remained in 18% of patients undergoing treatment.

Inotuzumab ozogamicin treats relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

From improved adherence to fewer visits to the pharmacy, medication synchronization offers significant benefits for patients.

Over the last few months, new developments have taken place within the biosimilar market including new drug approvals and guidance documents released by the FDA.

MJH Events team to leverage industry expertise of Specialty Pharmacy Times® editorial board in collaboration with NASP Board of Directors to develop industry leading content for September Annual Meeting.

NASP President Rebecca Shanahan discusses pressing topics in specialty pharmacy, including DIR fees and the potential impact of the Trump administration.

Few studies have examined the importance of socioeconomic risk factors on overall health.

New system could improve the implementation of pre-exposure prophylaxis-based care for HIV prevention.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses how specialty pharmacy can best utilize data analytics.

One round of investigational combination treatment may be more effective than long-term treatment for multiple sclerosis.

Efficacy of tocilizumab monotherapy was maintained or improved for up to 264 weeks.

Top news of the day from across the health care landscape.

Although PrEP is highly effective, few appropriate patients with HIV currently use it.

Long-acting antiretroviral maintains significant viral load reduction and increases CD4+ T cells in HIV.

Flawed patents challenged on blockbuster HCV drugs to allow generic production.

SMAC mimetics and immune checkpoint inhibitors, together, promote tumor immunity against deadly brain cancer.

The American Diabetes Association releases an update position statement reflecting the current diabetic neuropathy landscape.

Findings suggest that human genetics trigger mutations in the HIV viral genome.

Biosimilar costs 15% less than the reference product.

Top news of the day from across the health care landscape.